Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237594 · ClinicalTrials.gov registry record · Phase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
A Phase 1 study, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT07237594: Recruiting Phase 1 study, sponsored by Duke University.
NCT07237594 is a Phase 1 study that is actively recruiting participants, run by Duke University. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07237594, a Phase 1 study, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.
Primary Outcome
Participants will be assessed for AEs at each study visit. AEs are graded by NCI-CTCAE v5.0 criteria.
Interventions
- DRUG Secukinumab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
What NCT07237594 shows while recruiting
NCT07237594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Secukinumab Injection is the first listed.
NCT07237594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07237594 about?
NCT07237594 is a clinical study titled "IL-17 Blockade to Decrease irAEs (REPLAY)". The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune...
What is the current status of trial NCT07237594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2026-03-12. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07237594?
The interventions under investigation include: Secukinumab Injection (DRUG).
Who is sponsoring clinical trial NCT07237594?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07237594's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI